Last updated: July 11, 2026
- The case Bausch Health Companies Inc. v. Sun Pharmaceutical Industries Ltd., 2:26-cv-08573 is a federal patent litigation matter filed in the District of New Jersey.
- No operative filings, claims, asserted patents, accused products, or procedural posture (motion practice, transfer activity, scheduling orders, Markman status, settlement) are provided here, so a litigation summary cannot be produced without producing inaccuracies.
What is the litigation summary for Bausch Health v. Sun Pharmaceutical Industries, 2:26-cv-08573?
A complete litigation summary requires: the complaint and causes of action, the asserted patent list, the accused drug/labeling, relevant FDA Orange Book references (if Hatch-Waxman), and the most recent docket events.
Which patents does Bausch Health assert against Sun in 2:26-cv-08573?
A patent-by-patent analysis requires the complaint’s asserted claims and identified patents. Without that list, any statement would risk misidentification.
Are the asserted patents Orange Book-listed and tied to a specific FDA NDA/ANDA?
To determine whether the dispute is Orange Book centered, the docket and complaint must identify the drug name, NDA/ANDA numbers, Orange Book listing numbers, and patent use codes.
What product(s) did Sun challenge or market that triggered the Bausch suit?
A meaningful accused-product analysis requires the complaint’s descriptions (strength, dosage form, NDC, label, manufacturing site, ANDA paragraph references).
What is the procedural posture in 2:26-cv-08573 (motions, scheduling, Markman)?
A procedural summary requires docket events such as:
- complaint filing date
- answer/response deadlines
- motions to dismiss / transfer
- claim construction (Markman) dates
- pretrial orders
- stay pending PTO or IPR
- final trial date or settlement reports
No docket timeline or filings are available in the prompt.
What is the status of any Paragraph IV litigation related to 2:26-cv-08573?
Paragraph IV analysis depends on whether:
- the complaint alleges § 271(e)(2) with an ANDA notice,
- it identifies the ANDA number and date of notice,
- it ties to a particular Orange Book patent.
Those details must be taken from the case documents.
Has the parties’ dispute resulted in a settlement agreement or consent judgment?
Settlement status must be confirmed from:
- docket entries (e.g., “Stipulation of Dismissal,” “Settlement Agreement” references),
- court orders (dismissal with/without prejudice),
- joint motions reflecting license or launch carve-outs.
No such information is provided.
How strong is Bausch’s patent estate in this case?
Strength analysis requires:
- the claim set asserted,
- the independent/dependent claim mix,
- proximity to critical dates (filing, priority, prosecution history),
- known prior art and invalidation arguments raised in motions.
None of this is present.
What defenses has Sun raised (invalidity, non-infringement, unenforceability)?
Defense assessment requires reviewing:
- the answer,
- invalidity contentions,
- non-infringement contentions,
- inequitable conduct or § 112 arguments.
What generic entry risks does 2:26-cv-08573 create for Sun or other ANDA filers?
This requires identifying:
- the ANDA at issue,
- whether a court injunction is sought/entered,
- potential design-around space,
- any FDA approval timelines.
No ANDA linkage is provided.
How does the court typically handle cases filed in New Jersey for Orange Book/IP disputes?
General New Jersey handling patterns can be described only at a general level, but the user requested a litigation summary and analysis for a specific numbered case. Without the docket, a case-specific analysis cannot be completed.
Key Takeaways
- A case-specific litigation summary for Bausch Health Companies Inc. v. Sun Pharmaceutical Industries Ltd. (2:26-cv-08573) cannot be produced from the information provided.
- No asserted patents, accused products, Orange Book nexus, procedural milestones, or outcomes are included in the prompt; any attempt to fill those gaps would be speculative.
FAQs
- What court division is case 2:26-cv-08573 in and what does that imply for scheduling?
- Does 2:26-cv-08573 appear to be Hatch-Waxman ANDA litigation or something else?
- How can the asserted patents typically map to Orange Book listing codes in similar cases?
- What docket events usually signal claim construction, trial readiness, or settlement in these disputes?
- What injunction or launch-blocking outcomes are common if the patentee wins on infringement?
References
- Not available from the prompt.
